Print

Cancer Research Consortium of West Michigan

All Open Clinical Trials

Cancer clinical trials are research studies for developing better ways of detecting, treating, and eventually preventing cancer. By taking part in a clinical trial, you are among the first to receive new research treatments before they are widely available. Your participation in a clinical trial will influence the future direction of cancer care.

If you are interested in participating in a clinical trial, consult with your physician. Please note: clinical trials are not risk free. Patients must explore the options that are best for their individuals needs with the help of their physician.

Provided drugs are underlined

For more information, call the CRCWM Main office at 616.391.1230 or 800.336.5079

Brain/CNS

Cancer Type: Glioblastoma
Research Base: Alliance
Protocol: Alliance A071102

Alliance A071102: A Phase II/III Randomized Trial of Veliparib/Placebo in Combination with Adjuvant Temozolomide in Newly Diagnosed Glioblastoma with MGMT Promoter Hypermethylation

Cancer Type: MENINGIOMAS WITH SMO/AKT/NF2 MUTATIONS
Research Base: Alliance
Protocol: Alliance A071401

PHASE II TRIAL OF SMO/AKT/NF2 INHIBITORS IN PROGRESSIVE MENINGIOMAS WITH SMO/AKT/NF2 MUTATIONS

Cancer Type: Brain Metastases
Research Base: NRG
Protocol: NRG CC001

NRG CC001: A Randomized Phase III Trial of Memantine and Whole-Brain Radiotherapy with or Without Hippocampal Avoidance in Patients with Brain Metastases. 

Cancer Type: Hi-Grade Glioma
Research Base: Alliance
Protocol: Alliance A221101

Alliance A221101: A Phase III Randomized, Double-Blind Placebo Controlled Study. Armodafinil vs Placebo. Cancer-Related Fatigue in Patients with High Grade Glioma. 


 

Cancer Type: Medulloblastoma/PNET
Research Base: COG
Protocol: COG ACNS0332

COG-ACNS0332: Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients. Patients age > 3 and < 22 years at the time of diagnosis.

Cancer Type: Newly Diagnosed Ependymoma
Research Base: COG
Protocol: COG ACNS0831

COG ACNS0831: Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 years. Patients > 12 months and < 21 years of age.

Cancer Type: CNS Germ Cell Tumors
Research Base: COG
Protocol: COG ACNS1123

COG ACNS1123: Phase 2 Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors (CNS GCT). Patients must be ≥ 3 years and ≤ 21 years of age. TEMPORARY CLOSURE

Cancer Type: Neuroblastoma-Biology
Research Base: COG
Protocol: COG ANBL00B1

COG ANBL00B1: Neuroblastoma Classification Biology Studies. All newly diagnosed patients with suspected neuroblastoma, suspected ganglioneuroblastoma, or suspected ganglioneuroma/maturing subtype seen at COG institutions are eligible for this study. 

Breast

Cancer Type: Triple-Negative Invasive Breast Cancer
Research Base: NRG
Protocol: NRG BR003

NRG BR003: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

Cancer Type: Node Positive Her2 Negative Breast Cancer
Research Base: Alliance
Protocol: Alliance A011502

A RANDOMIZED PHASE III DOUBLE BLINDED PLACEBO CONTROLLED TRIAL OF ASPIRIN AS ADJUVANT THERAPY FOR NODE POSTIVE HER2 NEGATIVE BREAST CANCER: THE ABC TRIAL

Cancer Type: Breast cancer
Research Base: ECOG-ACRIN
Protocol: EA1141

Comparison of Abbreviated Breast MRI and Digital Breast Tomosynthesis in Breast Cancer Screening in Women with Dense Breasts

Cancer Type: Breast Cancer
Research Base: Wake Forest
Protocol: WF 97116

WF 97116:  A Phase 3 Randomized Placebo Controlled Clinical Trial of Donepezil in Chemotherapy Exposed Breast Cancer Survivors with Cognitive Impairment

Cancer Type: ER(+) NeoAdjuvant
Research Base: Alliance
Protocol: Alliance A011106

A011106: ALTernate approaches for clinical stage II or III Estrogen Receptor positive breast cancer NeoAdjuvant TrEatment (ALTERNATE) in postmenopausal women: a phase III study

Cancer Type: HER2 negative early breast Cancer
Research Base: AFT
Protocol: AFT-5 Pallas
PALbociclib CoLlaborative Adjuvant Study:
A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer  
Cancer Type: ER/PgR Any; Her2 Negative; Post Adjuvant
Research Base: NRG
Protocol: NSABP B-55

NSABP B55: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Multi-Center Phase III Study. Olaparib vs Placebo. Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy. 

Cancer Type: Triple-Negative Basal-Like Breast Cancer
Research Base: ECOG-ACRIN
Protocol: EA1131

ECOG EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy vs Capecitabine in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Cancer Type: High-Risk, ER/PR+ and HER2/neu -
Research Base: SWOG
Protocol: SWOG S1207

SWOG S1207: Phase III randomized trial. Endocrine Therapy + Everolimus/Placebo. High-risk hormone receptor positive and HER2/NEU negative breast cancer. Staging I-III.

Cancer Type: RT for (+)Node?Neo Chemo f/b surg?(-)Node
Research Base: NRG
Protocol: NSABP B-51

NSABP B-51: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy. 

Cancer Type: Triple(-); ypT1or ypN(+)
Research Base: SWOG
Protocol: SWOG S1418

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN+) after Neoadjuvant Chemotherapy

Cancer Type: ER/PR(+); Her2 Negative
Research Base: CTSU
Protocol: CTSU E2112

CTSU E2112: Phase III Trial;  Endocrine Therapy Plus Entinostat/Placebo; Patients with Hormone Receptor-Positive Advanced Breast Cancer

Cancer Type: Mets; Triple Negative
Research Base: SWOG
Protocol: SWOG S1416

Phase II Randomized Placebo-Controlled Trial of Cisplatin with or without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer

Cancer Type: HER2 Positive Breast Cancer w/Brain Mets
Research Base: NRG
Protocol: RTOG 1119

RTOG 1119: Phase II Randomized Study. WBRT +/- Lapatinib in patients with brain metastasis from HER2-Positive breast cancer. Stage IV.

Cancer Type: Metastatic Breast Cancer (MBC)
Research Base: Sarah Cannon
Protocol: SCRI BRE 203

SCRI BRE 203: A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR).  

Cancer Type: Locally Recurrent or Mets; 1st or 2nd Line
Research Base: ACCRU
Protocol: ACCRU RU011201I

ACCRU RU011201I A Randomized Phase III Trial of Eribulin vs Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer. Not available at Lakeland HealthCare
Staging: 1st or 2nd Line, Locally Recurrent or Metastatic Stage IV or Stage IIIC Not Amenable To Local Therapy, HER2(-). Treatment: Eribulin vs Paclitaxel

Cancer Type: Breast cancer
Research Base: Alliance
Protocol: Alliance A011401

Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer

Cancer Type: ER/PR+ Breast Cancer
Research Base: CTSU
Protocol: CTSU E1Z11

CTSU E1Z11: A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS) Specimen Processing Lab 2/24/14. Stage I - III Adenocarcinoma of the breast. Patients must be ER/PR+. Treatment: Anastrozole. 
 

Cancer Type: Breast Cancer
Research Base: Alliance
Protocol: Alliance A011104

Alliance A011104: Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women with Breast Cancer

Cancer Type: Stage I-III Breast or lymphoma
Research Base: Wake Forest
Protocol: WF 98213 - PREVENT

Preventing Anthracycline Cardiovascular Toxicity with Statins (PREVENT) - Newly diagnosed Stage I-III breast cancer (including inflammatory and newly diagnosed recurrent breast cancer) or lymphoma with a > 2 year life expectancy. Statin/atorvastatin or Placebo

Cancer Control

Cancer Type: SCLC
Research Base: NRG
Protocol: NRG CC003

NRG CC003: Randomized Phase II/III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer

Cancer Type: Breast cancer
Research Base: Alliance
Protocol: Alliance A011401

Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer

Cancer Type: Tissue Procurement
Research Base: NCI
Protocol: PDM 9846

PDM 9846: Patient-Derived Models Tissue Procurement Protocol for the National Cancer Institute (NCI)

Cancer Type: Cancer Care deliver
Research Base: SWOG
Protocol: SWOG S1415CD

A Pragmatic Trial to Evaluate a Guideline-Based Colony Stimulating Factor Standing Order Intervention and to Determine the Effectiveness of Colony Stimulating Factor Use as Prophylaxis for Patients Receiving Chemotherapy with Intermediate Risk for Febrile Neutropenia –Trial Assessing CSF Prescribing Effectiveness and Risk (“TrACER”)”

Cancer Type: Node Positive Her2 Negative Breast Cancer
Research Base: Alliance
Protocol: Alliance A011502

A RANDOMIZED PHASE III DOUBLE BLINDED PLACEBO CONTROLLED TRIAL OF ASPIRIN AS ADJUVANT THERAPY FOR NODE POSTIVE HER2 NEGATIVE BREAST CANCER: THE ABC TRIAL

Cancer Type: Evidence-Based Supportive Care
Research Base: COG
Protocol: COG ACCL15N1CD
 

COG ACCL15N1CD: Use of Evidence-Based Supportive Care Clinical Practice Guidelines in Pediatric Oncology

Cancer Type: Breast cancer
Research Base: ECOG-ACRIN
Protocol: EA1141

Comparison of Abbreviated Breast MRI and Digital Breast Tomosynthesis in Breast Cancer Screening in Women with Dense Breasts

Cancer Type: Breast Cancer
Research Base: Wake Forest
Protocol: WF 97116

WF 97116:  A Phase 3 Randomized Placebo Controlled Clinical Trial of Donepezil in Chemotherapy Exposed Breast Cancer Survivors with Cognitive Impairment

Cancer Type: Cognitive Impairment in Colorectal Cancer
Research Base: URCC
Protocol: URCC 16092

Phase II Study of Exercise and Low-Dose Ibuprofen for Cognitive Impairment in Colorectal Cancer Patients Receiving Chemotherapy

Cancer Type: Multisite - Screening
Research Base: NCI
Protocol: DCP-001
 

DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)

Cancer Type: Colorectal
Research Base: SWOG
Protocol: SWOG S1417CD

S1417CD: Implementation of a Prospective Financial Impact Assessment Tool in Patients with Metastatic Colorectal Cancer

Cancer Type: Symptom Management for Insomnia
Research Base: URCC
Protocol: URCC 14040 - YOCAS
 

URCC 14040: A Randomized Clinical Trial Comparing the Effectiveness of Yoga, Survivorship Health Education, and Cognitive Behavioral Therapy for Treating Insomnia in Cancer Survivors

Cancer Type: Hi-Grade Glioma
Research Base: Alliance
Protocol: Alliance A221101

Alliance A221101: A Phase III Randomized, Double-Blind Placebo Controlled Study. Armodafinil vs Placebo. Cancer-Related Fatigue in Patients with High Grade Glioma. 


 

Cancer Type: Cancer Control
Research Base: URCC
Protocol: URCC 13059 (GAP 70)

URCC 13059 (GAP 70): A Geriatric Assessment Intervention for Patients Aged 70 and Over Receiving Chemotherapy or Similar Agents for Advanced Cancer: Reducing Toxicity in Older Adults

Cancer Type: ER/PR+ Breast Cancer
Research Base: CTSU
Protocol: CTSU E1Z11

CTSU E1Z11: A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS) Specimen Processing Lab 2/24/14. Stage I - III Adenocarcinoma of the breast. Patients must be ER/PR+. Treatment: Anastrozole. 
 

Cancer Type: Head and Neck
Research Base: Wake Forest
Protocol: WF 97115

WF 97115: A Phase III Prospective Randomized Trial of Acupuncture for Treatment of Radiation-Induced Xerostomia in Patients with Head and Neck Cancer. 

Cancer Type: Stage I-III Breast or lymphoma
Research Base: Wake Forest
Protocol: WF 98213 - PREVENT

Preventing Anthracycline Cardiovascular Toxicity with Statins (PREVENT) - Newly diagnosed Stage I-III breast cancer (including inflammatory and newly diagnosed recurrent breast cancer) or lymphoma with a > 2 year life expectancy. Statin/atorvastatin or Placebo

Cancer Type: Ovarian, Fallopian Tube and Primary Peritoneal
Research Base: NRG
Protocol: GOG 0225

GOG 0225: Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression Free Survival? Stage II-IV Ovarian, Fallopian Tube or Primary Peritoneal at diagnosis. Patients must have completed all primary chemotherapy and consolidation therapy (if administered) at least 6 weeks, and no more than 6 months and 2 weeks prior to enrollment and must be in complete remission. 

Cancer Type: Colorectal
Research Base: SWOG
Protocol: SWOG S0820

SWOG S0820: A Double Blind Placebo-Controlled Trial. Eflornithine vs Sulindac vs Elfornithine + Sulindac to prevent recurrence of high risk adenomas and second primary colorectal cancers. Stage 0-III Colon Cancer, Phase III. 

Cancer Type: Colorectal Stage IV
Research Base: NSABP-F
Protocol: NSABP MPR-1

NSABP MPR-1: Patient Registry and Biospecimen Profiling Repository. Stage IV Colorectal Cancer.

Cancer Type: Brain Metastases
Research Base: NRG
Protocol: NRG CC001

NRG CC001: A Randomized Phase III Trial of Memantine and Whole-Brain Radiotherapy with or Without Hippocampal Avoidance in Patients with Brain Metastases. 

Cancer Type: Pediatric ALL
Research Base: COG
Protocol: COG ACCL1033

COG ACCL1033: A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL - Partial Closure: stratum Hispanic < 12 years old. Diagnosis of ALL at ≥ 1 year and ≤ 21 years of age, in first remission. 

Cancer Type: Multi-site Cancer Control
Research Base: COG
Protocol: COG ALTE03N1

COG ALTE03N1: Key Adverse Events after Childhood Cancer. Diagnosis of primary cancer at age 21 or younger, irrespective of current age.

Cancer Type: Multi-Site Cancer Control
Research Base: COG
Protocol: COG ALTE07C1

COG ALTE07C1: Neuropsychological, Social, Emotional and Behavioral Outcomes in Children with Cancer

Gastrointestinal

Cancer Type: Pancreas Adenocarcinoma Resected
Research Base: NRG
Protocol: RTOG 0848
RTOG 0848: A Phase II-R and A Phase III Trial Evaluating Both *Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma. 
Cancer Type: Pancreas
Research Base: Alliance
Protocol: Alliance A021501

PREOPERATIVE EXTENDED CHEMOTHERAPY VS. CHEMOTHERAPY PLUS HYPOFRACTIONATED RADIATION THERAPY FOR BORDERLINE RESECTABLE ADENOCARCINOMA OF THE HEAD OF THE PANCREAS

Cancer Type: Pancreatic Adenocarcinoma - Resectable
Research Base: SWOG
Protocol: SWOG S1505

SWOG S1505: Pancreatic Adenocarcinoma - Resectable; Perioperative mFOLFIRINOX vs Gemcitabine/Nab-Paclitaxel. Phase II Study. 

Cancer Type: Gastroenteropancreatic Neuroendocrine
Research Base: ECOG-ACRIN
Protocol: EA2142

EA2142: Randomized Phase II Study of Cisplatin and Etoposide versus Temozolomide and Capecitabine in Patients with Advanced G3 Non-Small Cell Gastroenteropancreatic Neuroendocrine Carcinomas 

Cancer Type: Metastatic Pancreatic Cancer
Research Base: SWOG
Protocol: SWOG S1513

S1513:  RANDOMIZED PHASE II STUDY OF 2ND LINE FOLFIRI VERSUS MODIFIED FOLFIRI WITH PARPINHIBITOR ABT-888 (VELIPARIB) (NSC-737664) IN METASTATIC PANCREATIC CANCER

Cancer Type: Advanced Rectal Cancer
Research Base: NCI
Protocol: NCCTG N1048
 

N1048: A Phase II/III trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision

Cancer Type: Rectal
Research Base: NRG
Protocol: NRG GI002

A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer

Cancer Type: Colorectal Stage IV
Research Base: NSABP-F
Protocol: NSABP MPR-1

NSABP MPR-1: Patient Registry and Biospecimen Profiling Repository. Stage IV Colorectal Cancer.

Cancer Type: Colorectal
Research Base: SWOG
Protocol: SWOG S0820

SWOG S0820: A Double Blind Placebo-Controlled Trial. Eflornithine vs Sulindac vs Elfornithine + Sulindac to prevent recurrence of high risk adenomas and second primary colorectal cancers. Stage 0-III Colon Cancer, Phase III. 

Cancer Type: Colorectal
Research Base: SWOG
Protocol: SWOG S1417CD

S1417CD: Implementation of a Prospective Financial Impact Assessment Tool in Patients with Metastatic Colorectal Cancer

Cancer Type: Hepatoblastoma
Research Base: COG
Protocol: COG AHEP0731

COG AHEP0731: Treatment of Children with All Stages of Hepatoblastoma with Temsirolimus (IND#122782, NSC#683864) Added to High Risk Stratum Treatment. Patients must be < 21 years at the time of diagnosis.

Genitourinary

Cancer Type: Papillary Renal Carcinoma
Research Base: SWOG
Protocol: SWOG S1500

A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)

Cancer Type: Bladder Cancer
Research Base: SWOG
Protocol: SWOG S1314

SWOG S1314: Phase II Study of Co-Expression Extrapoliation (COXEN) with Neo-Adjuvant Chemotherapy for Localized, Muscle Invasive Bladder Cancer

Cancer Type: Prostate Cancer
Research Base: NRG
Protocol: RTOG 0924

RTOG 0924: Phase III Randomized Trial. RT (+/- whole pelvis) plus androgen deprivation therapy (short term therapy vs. long term therapy) in unfavorable intermediate or favorable high risk prostate cancer:  

Cancer Type: Germ Cell Tumor
Research Base: Alliance
Protocol: Alliance A031102

Alliance A031102: GERM CELL TUMORS/Relapsed or Refractory; Male Only; Comparing Conventional-Dose Chemotherapy Using paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by high-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment. Phase III Trial. 

Cancer Type: Renal-Biology
Research Base: COG
Protocol: COG AREN03B2

COG AREN03B2: Renal Tumors Classification, Biology, and Banking Study. Patients must be < 30 years old at the time of diagnosis.

Gynecologic

Cancer Type: Cervical Carcinoma
Research Base: NRG
Protocol: RTOG 0724
 

RTOG 0724: Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy With or Without Adjuvant Chemotherapy in High-Risk Patients with Early-stage Cervical Carcinoma Following Radical Hysterectomy - 

Cancer Type: HRD-Positive Advanced Ovarian Cancer
Research Base: NRG
Protocol: GOG 3012

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with HRD-Positive Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

Cancer Type: Stage I/IIA Cervical Cancer
Research Base: NRG
Protocol: GOG 0263
 

GOG 0263: Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy; 

Cancer Type: GYN-newly diagnosed, bulky stage
Research Base: NRG
Protocol: NRG GY006

NRG GY006: A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer. 

Cancer Type: GYN-Platinum Sensitive
Research Base: NRG
Protocol: NRG GY004

NRG GY004: A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. 

Cancer Type: GYN-Platinum Resistant
Research Base: NRG
Protocol: NRG GY005

NRG GY005: A Randomized Phase II/III study of the combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone, or Standard of care chemotherapy in women with recurrent platinum-resistant or -refractory ovarian, fallopian tube, or primary peritoneal cancer (COCOS). 

Cancer Type: Endometrial
Research Base: NRG
Protocol: GOG 0286B

GOG 286B:  Randomized PHASE II/III Study. Carboplatin/Paclitaxel + Metformin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer. 

Cancer Type: Ovarian, Fallopian Tube and Primary Peritoneal
Research Base: NRG
Protocol: GOG 0225

GOG 0225: Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression Free Survival? Stage II-IV Ovarian, Fallopian Tube or Primary Peritoneal at diagnosis. Patients must have completed all primary chemotherapy and consolidation therapy (if administered) at least 6 weeks, and no more than 6 months and 2 weeks prior to enrollment and must be in complete remission. 

Head and Neck

Cancer Type: Head and Neck
Research Base: ECOG-ACRIN
Protocol: EA3132

EA3132: Phase II Randomized Trial of Adjuvant Radiotherapy with or Without Cisplatin for p53 Mutated, Surgically Resected Squamous Cell Carcinoma of the Head and Neck

Cancer Type: Head and Neck
Research Base: NRG
Protocol: RTOG 0920
 

RTOG 0920: A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer - 

Cancer Type: Head and Neck
Research Base: Wake Forest
Protocol: WF 97115

WF 97115: A Phase III Prospective Randomized Trial of Acupuncture for Treatment of Radiation-Induced Xerostomia in Patients with Head and Neck Cancer. 

Leukemia

Cancer Type: Acute Lymphoblastic Leukemia (ALL)
Research Base: COG
Protocol: COG AALL15P1

COG AALL15P1: A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (IND# 133688, NSC# 102816) to Chemotherapy in Infants with Acute Lymphoblastic Leukemia (ALL) and KMT2A (MLL) Gene Rearrangement

Infants less than 1 year of age on the date of diagnosis are eligible; infants must be >36 weeks gestational age at the time of enrollment.

Cancer Type: Leukemia
Research Base: ECOG-ACRIN
Protocol: E1910
 

E1910: A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adult;

Cancer Type: Leukemia and Lymphoma
Research Base: BMT CTN
Protocol: BMTCTN 1101

Multi-center, Phase III, Randomized Trial of Reduced Intensity Conditioning and Transplantation of Double Unrelated Umbilical Cord Blood versus HLA-Haploidentical Related Bone Marrow for Patients with Hematologic Malignancies 

Cancer Type: Myelodysplastic Syndromes
Research Base: ECOG-ACRIN
Protocol: NHLBI-MDS

The National Myelodysplastic Syndromes (MDS) Study

Cancer Type: AML
Research Base: CTSU
Protocol: CTSU E2906

E2906:  Phase III Randomized Trial of Clofarabine as Induction and Post- Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age ≥ 60 Years). Not available at Lakeland Healthcare.

Cancer Type: AML
Research Base: COG
Protocol: COG AAML1531

COG-AAML1531: Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome

Children with Down syndrome > 90 days and < 4 years of age at diagnosis of AML or Myelodysplastic Syndrome (MDS) 

Cancer Type: B-ALL Relapse
Research Base: COG
Protocol: COG AALL1331

COG AALL1331: Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND#100135, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)

Age - Patients ≥1 year and < 31 years of age at the time of relapse will be eligible.

Cancer Type: Acute Promyelocytic Leukemia (APL)
Research Base: COG
Protocol: COG AAML1331
COG AAML1331: A Phase III Study for Patients with Newly Diagnosed Acute Promyelocytic
Leukemia (APL) using Arsenic Trioxide and All-Trans Retinoic Acid
 
Patient must be ≥ 12 months and < 22 years of age at first diagnosis of APL
Cancer Type: T-ALL & T-LLy
Research Base: COG
Protocol: COG AALL1231

COG AALL1231: A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL) and T- Lymphoblastic Lymphoma (T-LLy). All patients must be > 1 and < 31 years of age. 

Cancer Type: Leukemia ALL
Research Base: COG
Protocol: COG AALL05B1

COG-AALL05B1: Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens. Age <31 years of age at the time of initial diagnosis of ALL.

Cancer Type: ALL-Ancillary
Research Base: COG
Protocol: COG AALL08B1

COG AALL08B1: Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL).  < 31 years of age at diagnosis of acute leukemia. 

Cancer Type: ALL
Research Base: COG
Protocol: COG AALL0932

COG-AALL0932: Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-lineage Lymphoblastic Lymphoma (B-LLy). Patients must be > 365 days and < 10 years of age

Cancer Type: High Risk B-ALL
Research Base: COG
Protocol: COG AALL1131

COG AALL1131: A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (IND#73789, NSC#732517) in Patients with Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations

Patients must be > 365 days and < 31 years of age



 

Cancer Type: Pediatric ALL
Research Base: COG
Protocol: COG ACCL1033

COG ACCL1033: A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL - Partial Closure: stratum Hispanic < 12 years old. Diagnosis of ALL at ≥ 1 year and ≤ 21 years of age, in first remission. 

Lung

Cancer Type: Non-Small Cell Lung
Research Base: Alliance
Protocol: Alliance A151216

Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

Sub-Studies to ALCHEMIST: A081105,  E4512 and EA5142

Cancer Type: Squamous Cell Lung Cancer
Research Base: SWOG
Protocol: SWOG S1400G

A Phase II Study of Talazoparib (BMN 673) in Patients with Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)

Cancer Type: Non-Small Cell Lung
Research Base: CTSU
Protocol: ECOG E4512

ECOG E4512: Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib/Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

Cancer Type: NSCLC
Research Base: ECOG-ACRIN
Protocol: EA5142

EA5142: Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) – A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers

Cancer Type: Non-Small Cell Lung
Research Base: Alliance
Protocol: Alliance A081105

Alliance A081105: Randomized Double Blind study of Erlotinib/Placebo in patients with completely resected epidermal growth factor recepter (EGFR) mutant non-small cell lung cancer (NSCLC)

Cancer Type: NSCLC
Research Base: NRG
Protocol: RTOG 1306

RTOG 1306: A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer (NSCLC) 

Cancer Type: Non Small cell Lung Cancer
Research Base: SWOG
Protocol: SWOG S1206

A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy with Carboplatin and Paclitaxel for Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC), (NCI Study Number 8811).

Cancer Type: NSCLC
Research Base: SWOG
Protocol: SWOG S1403

SWOG S1403: A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients with Advanced, EGFR Mutation Positive Non-Small Cell Lung Cancer (NSCLC)

Cancer Type: Squamous Cell Lung Cancer
Research Base: SWOG
Protocol: SWOG S1400

SWOG S1400: A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer

LUNG-MAP Study - Composed of 4 sub-study protocols, 1400B, 1400C, 1400D, and S1400I

Cancer Type: Squamous Cell Lung Cancer
Research Base: SWOG
Protocol: SWOG S1400I

SWOG S1400I - A Phase III Randomized Study of Nivolumab plus Ipilimumab versus Nivolumab for Previously Treated Patients with Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (LUNG-MAP SUB-STUDY)

Cancer Type: SCLC
Research Base: NRG
Protocol: NRG CC003

NRG CC003: Randomized Phase II/III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer

Cancer Type: Limited Small Cell Lung Cancer
Research Base: Alliance
Protocol: CALGB 30610
 

CALGB 30610: Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin or Carboplatin and Etoposide

Lymphoma

Cancer Type: Lymphoma
Research Base: Alliance
Protocol: Alliance A051301

A RANDOMIZED DOUBLE-BLIND PHASE III STUDY OF IBRUTINIB DURING AND FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANTATION VERSUS PLACEBO IN PATIENTSWITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA OF THE ACTIVATED B-CELL SUBTYPE

Cancer Type: Leukemia and Lymphoma
Research Base: BMT CTN
Protocol: BMTCTN 1101

Multi-center, Phase III, Randomized Trial of Reduced Intensity Conditioning and Transplantation of Double Unrelated Umbilical Cord Blood versus HLA-Haploidentical Related Bone Marrow for Patients with Hematologic Malignancies 

Cancer Type: T-ALL & T-LLy
Research Base: COG
Protocol: COG AALL1231

COG AALL1231: A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL) and T- Lymphoblastic Lymphoma (T-LLy). All patients must be > 1 and < 31 years of age. 

Cancer Type: Hodgkin Lymphoma (cHL)
Research Base: COG
Protocol: COG AHOD1331

COG-AHOD1331: A Randomized Phase III Study of Brentuximab vedotin (IND #117117) for Newly Diagnosed Classical Hodgkin Lymphoma (cHL) in Children and Adolescents

Ages > 2 - < 19 years

Cancer Type: ALCL
Research Base: COG
Protocol: COG ANHL12P1

COG ANHL12P1: A Randomized Phase 2 study of Brentuximab Vedotin (NSC# 749710) and Crizotinib (NSC# 749005) in Patients with Newly Diagnosed Anaplastic Large Cell Lymphoma (ALCL) IND #117117. TEMPORARY CLOSURE

Patient must be < 22 years of age.

Cancer Type: Misc-Lymphoma
Research Base: COG
Protocol: COG ALTE11C1

COG ALTE11C1: Longitudinal Assessment of Ovarian Reserve in Adolescents with Lymphoma.

Patients must be < 30 years of age.

Cancer Type: Lymphoma-NHL Registry
Research Base: COG
Protocol: COG ANHL04B1

COG ANHL04B1: Rare and Cutaneous Non-Hodgkin Lymphoma Registry. Age 0-20.99 years.

Melanoma

Cancer Type: BRAF V600E/K Mutant Melanoma
Research Base: SWOG
Protocol: SWOG S1320

SWOG S1320: A Randomized Phase II Trial Of Intermittent Versus Continuous Dosing Of Dabrafenib (NSC-763760) And Trametinib (NSC-763093) In BRAF V600E/K Mutant Melanoma 

 

 

Cancer Type: Melanoma-unresectable
Research Base: ECOG-ACRIN
Protocol: ECOG EA6141

ECOG EA6141: STAGE III/IV/Unresectable Melanoma; Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab; Phase II/III Trial. 

Cancer Type: Melanoma
Research Base: ECOG-ACRIN
Protocol: ECOG EA6134

ECOG EA6134 - A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma; 

Multisite

Cancer Type: Rare Tumors
Research Base: SWOG
Protocol: SWOG S1609 DART

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors - TEMP CLOSED

Cancer Type: Multisite
Research Base: ASCO
Protocol: TAPUR

TAPUR - Targeted Agent and Profiling Utilization Registry Study

Cancer Type: Molecular
Research Base: ECOG-ACRIN
Protocol: EAQ 152 MATCH COMET

A Randomized Study of Pre-disclosure Genetic Education v. Usual Care in Tumor Profiling for Advanced Cancer and a Pilot Study of Remote Genetic Counseling for Participants with Potential Germline Mutations Identified on Tumor Profiling

Cancer Type: Molecular
Research Base: ECOG-ACRIN
Protocol: EAY131 - MATCH
EAY131 - 'MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas; Molecular Analysis for Therapy Choice    'MATCH'
Cancer Type: Molecular
Research Base: ECOG-ACRIN
Protocol: EAY131 - MATCH Protocol A

MATCH - Subprotocol A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment 

Cancer Type: Molecular
Research Base: ECOG-ACRIN
Protocol: EAY131 - MATCH Protocol B

MATCH - Subprotocol B: Phase II Study of Afatinib in Patients with Tumors with HER2 Activating Mutations. 

Cancer Type: Molecular
Research Base: ECOG-ACRIN
Protocol: EAY131 - MATCH Protocol C1

MATCH Subprotocol-C1: Crizotinib in Patients with Tumors with MET Amplification

Cancer Type: Molecular
Research Base: ECOG-ACRIN
Protocol: EAY131 - MATCH Protocol C2

MATCH Subprotocol-C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion

Cancer Type: Molecular
Research Base: ECOG-ACRIN
Protocol: EAY131 - MATCH Protocol E

MATCH - Subprotocol E: AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR.

Cancer Type: Molecular
Research Base: ECOG-ACRIN
Protocol: EAY131 - MATCH Protocol F

MATCH - Subprotocol F: Crizotinib in Patients with Tumors (Other Than Adenocarcinoma of Lung or ALCL) with ALK Translocations. 

Cancer Type: Molecular
Research Base: ECOG-ACRIN
Protocol: EAY131 - MATCH Protocol G

MATCH - Subprotocol G: Phase II Study of Crizotinib in Patients with ROS1 Translocations (Other Than Patients with Non-Small Cell Lung Cancer). 

Cancer Type: Molecular
Research Base: ECOG-ACRIN
Protocol: EAY131 - MATCH Protocol H

MATCH - Subprotocol H: Phase II Study of Dabrafenib and Trametinib in Patients with Tumors with BRAF V600E or V600K Mutations (Excluding Melanoma and Thyroid Cancer).

Cancer Type: Molecular
Research Base: ECOG-ACRIN
Protocol: EAY131 - MATCH Protocol J

Trastuzumab and Pertuzumab (HP) in Patients with Non-Breast, Non-Gastric/GEJ Cancers with HER2 Amplification

Cancer Type: Molecular
Research Base: ECOG-ACRIN
Protocol: EAY131 - MATCH Protocol L

Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations

Cancer Type: Molecular
Research Base: ECOG-ACRIN
Protocol: EAY131 - MATCH Protocol M

Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations

Cancer Type: Molecular
Research Base: ECOG-ACRIN
Protocol: EAY131 - MATCH Protocol N

MATCH Subprotocol N: Phase II Study of PI3K Beta Specific Inhibitor, GSK2636771, in Patients with Tumors with PTEN Mutation or Deletion, with PTEN Expression on IHC

Cancer Type: Molecular
Research Base: ECOG-ACRIN
Protocol: EAY131 - MATCH Protocol R

MATCH - Subprotocol R: Phase II Study of Trametinib in Patients with BRAF Fusions, or with Non-V600E, Non-V600K BRAF Mutations.

Cancer Type: Molecular
Research Base: ECOG-ACRIN
Protocol: EAY131 - MATCH Protocol S1

MATCH Treatment Subprotocol S1: Phase II Study of Trametinib in Patients with Tumors with NF1 mutations

Cancer Type: Molecular
Research Base: ECOG-ACRIN
Protocol: EAY131 - MATCH Protocol S2

MATCH Subprotocol S2: Phase II Study of Trametinib in Patients with Tumors with GNAQ or GNA11 mutations

Cancer Type: Molecular
Research Base: ECOG-ACRIN
Protocol: EAY131 - MATCH Protocol T

MATCH Subprotocol T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations

Cancer Type: Molecular
Research Base: ECOG-ACRIN
Protocol: EAY131 - MATCH Protocol U

MATCH - Subprotocol U: VS-6063 (defactinib) in Patients with Tumors with NF2 Loss.

Cancer Type: Molecular
Research Base: ECOG-ACRIN
Protocol: EAY131 - MATCH Protocol V

MATCH - Subprotocol V: Phase II Study of Sunitinib in Patients with Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor). 

Cancer Type: Molecular
Research Base: ECOG-ACRIN
Protocol: EAY131 - MATCH Protocol W

EAY131-W:  Phase II Study of AZD4547 in Patients with Tumors with Aberrations in the FGFR Pathway

Cancer Type: Molecular
Research Base: ECOG-ACRIN
Protocol: EAY131 - MATCH Protocol X

MATCH Subprotocol X: Phase II Study of Dasatinib in Patients with Tumors with DDR2 Mutations

Cancer Type: Molecular
Research Base: ECOG-ACRIN
Protocol: EAY131 - MATCH Protocol Z1B

MATCH subprotocol-Z1B: Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CCND1, 2, 3 Amplification and Rb Protein Expression by IHC

Cancer Type: Molecular
Research Base: ECOG-ACRIN
Protocol: EAY131 - MATCH Protocol Z1C

Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CDK4 or CDK6 Amplification and Rb Protein Expression by IHC

Cancer Type: Molecular
Research Base: ECOG-ACRIN
Protocol: EAY131 - MATCH Protocol Z1D

MATCH Subprotocol -Z1D: Nivolumab in Patients with Tumors with Mismatch Repair Deficiency (Excluding Colorectal Cancer)

Cancer Type: Molecular
Research Base: ECOG-ACRIN
Protocol: EAY131 - MATCH Protocol Z1E

Testing LOXO-101 as potentially targeted treatment in cancers with NTRK genetic changes

Cancer Type: Molecular
Research Base: ECOG-ACRIN
Protocol: EAY131 - MATCH Protocol Z1I

Testing AZD1775 as a possible treatment in people who have cancer with BRCA mutations

Cancer Type: Cancer Control
Research Base: URCC
Protocol: URCC 13059 (GAP 70)

URCC 13059 (GAP 70): A Geriatric Assessment Intervention for Patients Aged 70 and Over Receiving Chemotherapy or Similar Agents for Advanced Cancer: Reducing Toxicity in Older Adults

Cancer Type: Multisite - Screening
Research Base: NCI
Protocol: DCP-001
 

DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)

Cancer Type: Tissue Procurement
Research Base: NCI
Protocol: PDM 9846

PDM 9846: Patient-Derived Models Tissue Procurement Protocol for the National Cancer Institute (NCI)

Cancer Type: All patients
Research Base: COG
Protocol: COG APEC14B1

Project:EveryChild A Registry, Eligibility Screening, Biology and Outcome Study

Subjects must be ≤ 25 years of age at time of original diagnosis, except for patients who are being screened specifically for eligibility onto a COG (or COG participating NCTN) therapeutic study, for whom there is a higher upper age limit.

Cancer Type: Cancer Registry
Research Base: COG
Protocol: COG ACCRN07
 

COG ACCRN07: Protocol for the Enrollment on the Official COG Registry, The Childhood Cancer Research Network (CCRN)

Cancer Type: Multi-site Cancer Control
Research Base: COG
Protocol: COG ALTE03N1

COG ALTE03N1: Key Adverse Events after Childhood Cancer. Diagnosis of primary cancer at age 21 or younger, irrespective of current age.

Cancer Type: Multisite Long Term Follow-up
Research Base: COG
Protocol: COG ALTE05N1

COG ALTE05N1: Umbrella Long-term Follow-up Protocol. Only available to patients already enrolled on a COG intervention protocol.

Cancer Type: Multi-Site Cancer Control
Research Base: COG
Protocol: COG ALTE07C1

COG ALTE07C1: Neuropsychological, Social, Emotional and Behavioral Outcomes in Children with Cancer

Myeloma

Cancer Type: Solitary Plasmacytoma of Bone
Research Base: Alliance
Protocol: Alliance A061402

A061402: Solitary Plasmacytoma of Bone: Randomized Phase III Trial to Evaluate Treatment with Adjuvant Systemic Treatment and Zoledronic Acid versus Zoledronic Acid after Definite Radiation Therapy

Cancer Type: Myeloma
Research Base: Alliance
Protocol: Alliance A061202

A Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib VS. Pomalidomide and Dexamethasone for Patients with Multiple Myeloma Refractory to Lenalidomide and Proteasome Inhibitor-Based Therapy.

Cancer Type: High Risk Multiple Myeloma
Research Base: SWOG
Protocol: SWOG S1211

SWOG S1211: A Randomized Phase II Study. RVD +/- Elotuzumab. for newly diagnosed high risk multiple myeloma (HRMM).  

Cancer Type: Myeloma
Research Base: ECOG-ACRIN
Protocol: E1A11
 

E1A11: Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)

Neuroblastoma

Cancer Type: NBL
Research Base: COG
Protocol: COG ANBL1232

Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma

Cancer Type: Refractory, Relapsed or Progressive Neuroblastoma
Research Base: COG
Protocol: COG ANBL1221

COG ANBL1221: A Phase II Randomized Trial of Irinotecan/Temozolomide with Temsirolimus (NSC# 683864, IND# 61010) or Chimeric 14.18 Antibody (ch14.18) (NSC# 764038, IND# 4308) in Children with Refractory, Relapsed or Progressive Neuroblastoma. Patients of all ages. TEMPORARY CLOSURE

Cancer Type: Neuroblastoma-Biology
Research Base: COG
Protocol: COG ANBL00B1

COG ANBL00B1: Neuroblastoma Classification Biology Studies. All newly diagnosed patients with suspected neuroblastoma, suspected ganglioneuroblastoma, or suspected ganglioneuroma/maturing subtype seen at COG institutions are eligible for this study. 

Sarcoma

Cancer Type: Ewing Sarcoma
Research Base: COG
Protocol: COG AEWS07B1

COG AEWS07B1: A Children's Oncology Group Protocol for Collecting and Banking Ewing Sarcoma Specimens

Cancer Type: Osteosarcoma-Biology
Research Base: COG
Protocol: COG AOST06B1

COG AOST06B1: A Children's Oncology Group Protocol for Collecting and Banking Osteosarcoma Specimens. There are no age limitations on this study.

Cancer Type: Soft Tissue Sarcomas
Research Base: COG
Protocol: COG ARST1321

COG ARST1321: Pazopanib Neoadjuvant Trial In Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754, IND# 118613) 

Patients must be ≥ 2 years at the time of the biopsy that established the diagnosis of NRSTS will be eligible

Cancer Type: Ewing Sarcoma
Research Base: COG
Protocol: COG AEWS1221

COG-AEWS1221: Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma 

Patients ≤ 50 years of age at enrollment will be eligible for this study.

Cancer Type: Osteosarcoma
Research Base: COG
Protocol: COG AOST1421

COG AOST1421: A Phase 2 Study of Human-Mouse Chimeric Anti-Disialoganglioside Monoclonal Antibody ch14.18 (Dinutuximab, NSC# 764038, IND# 4308) in Combination with Sargramostim (GM-CSF) in Patients with Recurrent Osteosarcoma 

Patients must be less than 30 years of age at enrollment.

Cancer Type: Osteosarcoma
Research Base: COG
Protocol: COG AOST1321

COG-AOST1321: Phase 2 Study of Denosumab (IND#127430, NSC# 744010), a RANK Ligand Antibody, for Recurrent or Refractory Osteosarcoma - TEMPORARY CLOSURE

Patients must be equal to or greater than 11 years of age but less than 50 years of age at the time of enrollment.

Cancer Type: IR Rhabdomyosarcoma
Research Base: COG
Protocol: COG ARST1431

COG-ARST1431: A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864, IND# 122782) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS) TEMPORARY CLOSURE

Feasibility Phase: Patients must be < 21 years of age at the time of enrollment.
Efficacy Phase: Patients must be ≤ 40 years of age at the time of enrollment.